Abstract: The invention concerns a compound formed by functionalised micro- or nanoparticles covalently associated with rheology-modifying polymers. The invention is characterised in that the functionalised micro- or nanoparticles are functionalised inorganic or metal oxide micro- or nanoparticles, in particular aluminium oxide (Al2O3), copper oxide (CuO), iron oxide (Fe3O4 or ?-Fe2O3), magnesium oxide (MgO), silica (SiO2), titanium dioxide (TiO2) or zinc oxide (ZnO), having a nominal diameter of between 1 and 1500 nm; and in that the rheology-modifying or -adapting polymers are chosen from non-associative polymers or associative polymers. The invention applies to protection or decontamination of the skin.
Type:
Application
Filed:
February 21, 2014
Publication date:
December 31, 2015
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA ANTIPOLIS
Inventors:
Frédéric Guittard, Sonia Amigoni, Elisabeth Taffin de Givenchy, Arnaud Zenerino, Denis Josse
Abstract: Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.
Type:
Grant
Filed:
April 17, 2012
Date of Patent:
November 3, 2015
Assignees:
Universite Nice Sophia Antipolis, Centre National De La Recherche Scientifique, Institut National De La Sante De La Recherche Medicale
Inventors:
Rachid Benhida, Patrick Auberger, Vincent Malnuit, Mohsine Driowya, Alexandre Puissant, Guillaume Robert
Abstract: A method of treating cancer is described. The method includes administering to a person in need thereof an effective amount of a ligand selected from the group consisting of shRNA, igmesine, and (+) pentazocine, wherein the ligand modulates a channel macrocomplex comprising a sigma-1 receptor and an ion channel.
Type:
Application
Filed:
March 10, 2015
Publication date:
July 2, 2015
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, UNIVERSITE NICE SOPHIA ANTIPOLIS
Abstract: The invention relates to an in vitro analysis method for predicting resistance to azacitidine treatment in a patient, using the BCL2L10 protein contained in a sample of biological fluid taken from said patient, and also biological molecules which specifically bind the BCL2L10 protein. It is characterized in that a sample of biological fluid is recovered from a patient; the percentage of total cells in said biological fluid expressing the BCL2L10 protein is calculated; this calculated percentage is compared with a reference threshold value, this threshold value being between 20% and 60%; and resistance to azacitidine treatment is diagnosed in a patient who has a percentage of cells expressing the BCL2L10 protein in said biological fluid which is greater than said reference value.
Type:
Application
Filed:
February 28, 2013
Publication date:
April 2, 2015
Applicants:
UNIVERSITÉ NICE SOPHIA ANTIPOLIS, CENTRE HOSPITALIER UNIVERSITAIRE DE NICE
Inventors:
Thomas Cluzeau, Patrick Auberger, Guillaume Robert, Frédéric Luciano
Abstract: A method of treatment of a human patient suffering from myeloid neoplasias, includes administrating a therapeutically effective amount of 5-aminoimidazole-4-carboxamide (acadesine), acadesine precursors or acadesine derivatives.
Type:
Grant
Filed:
October 26, 2011
Date of Patent:
November 25, 2014
Assignees:
Universite Nice Sophia Antipolis, Centre Hospitalier Universitaire de Nice, INSERM (Institut National de la Sante et de la Recherche Medicale)
Inventors:
Thomas Cluzeau, Patrick Auberger, Guillaume Robert
Abstract: The present invention relates to novel aminosteroid derivatives substituted in position 3 andor 6, and to the use thereof in the context of the treatment of type 2 diabetes and of insulin resistance.
Type:
Application
Filed:
October 16, 2012
Publication date:
September 4, 2014
Applicants:
UNIVERSITE NICE SOPHIA ANTIPOLIS, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante Et de la Recherche Medicate), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE
Inventors:
Roland Marinus Theodorus Govers, Jean-Michel Brunel
Abstract: The invention relates to a collector mirror (2) which is a component of a solar concentrator comprising linear Fresnel mirrors. The collector mirror (2) includes a reflective strip. The collector mirror (2) is provided with a device capable of generating a negative pressure (AP) behind the reflective strip (6).
Type:
Application
Filed:
July 13, 2012
Publication date:
June 19, 2014
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA-ANTIPOLIS
Abstract: The present invention relates to the use of the Sigma-1 receptor (Sig1R) in the context of the post-transcriptional regulation of the membrane expression of ion channels. The present invention can be used in the field of the treatment of diseases involving ion channels. These are, for example, nervous system diseases, neurodegenerative diseases, heart diseases, and cancer.
Type:
Application
Filed:
January 31, 2012
Publication date:
November 28, 2013
Applicants:
UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
Abstract: The invention relates to a method of treatment of a human patient suffering from Myeloid Neoplasias, comprising administrating a therapeutically effective amount of acadesine, acadesine precursors or acadesine derivatives.
Type:
Application
Filed:
October 26, 2011
Publication date:
May 2, 2013
Applicants:
Universite Nice Sophia Antipolis, INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Hospitalier Universitaire de Nice
Inventors:
Thomas Cluzeau, Patrick Auberger, Guillaume Robert
Abstract: The invention relates to the use of the peptide toxin APETx2 that blocks the ASIC3 cationic channels and that is derived from the Anthopleura elegantissima sea anemone, and to the use of the analogs and derivatives thereof as a drug, particularly as an analgesic pain associated with the activation of ASIC3 (Acid Sensing Ion Channel 3) channels, in particular pain occurring upon an inflammation and potentially upon any painful situation associated with tissue acidosis (ischemiae, fractures, hematoma, oedema, phlyctena, local infections, tissue lesions, ocular wounds, tumours, etc.).
Type:
Grant
Filed:
June 4, 2009
Date of Patent:
January 22, 2013
Assignees:
Centre National de la Recherche Scientifique-CNRS, Universite Nice Sophia Antipolis
Inventors:
Emmanuel Deval, Sylvie Diochot, Michel Lazdunski, Eric Lingueglia, Jacques Noel
Abstract: The invention relates to the use of the peptide toxin APETx2 that blocks the ASIC3 cationic channels and that is derived from the Anthopleura elegantissima sea anemone, and to the use of the analogs and derivatives thereof as a drug, particularly as an analgesic pain associated with the activation of ASIC3 (Acid Sensing Ion Channel 3) channels, in particular pain occurring upon an inflammation and potentially upon any painful situation associated with tissue acidosis (ischemiae, fractures, hematoma, oedema, phlyctena, local infections, tissue lesions, ocular wounds, tumours, etc.
Type:
Application
Filed:
June 4, 2009
Publication date:
June 23, 2011
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS-, UNIVERSITE NICE SOPHIA ANTIPOLIS
Inventors:
Emmanuel Deval, Sylvie Diochot, Michel Lazdunski, Eric Lingueglia, Jacques Noel